文献速递肺血管病与心包/心肌炎血脂与心血管预防

司美格鲁肽在外周动脉疾病患者中的疗效性别差异:STRIDE试验

Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-08-31

STRIDE试验的事后分析比较了司美格鲁肽1.0 mg在外周动脉疾病合并2型糖尿病患者中的疗效是否存在性别差异。共纳入792例参与者(女性195例,男性597例),主要终点为第52周恒定负荷平板试验中最大步行距离(MWD)相对基线的比值。结果显示,司美格鲁肽改善功能结局的疗效在两性中一致,但女性基线特征和治疗模式与男性存在差异。

要点

  • 司美格鲁肽1.0 mg改善外周动脉疾病患者功能结局的疗效无显著性别差异。
  • 女性外周动脉疾病患者基线特征与男性不同,如更年轻、合并冠心病和心衰比例更低。
  • 外周动脉疾病临床试验应重视性别特异性评估。

核心结论

  • 在STRIDE试验的事后分析中,司美格鲁肽1.0 mg对早期症状性外周动脉疾病合并2型糖尿病患者的函数结局改善在两性中一致。
  • 女性外周动脉疾病患者基线人口学和治疗模式与男性存在差异,提示在外周动脉疾病试验中进行性别特异性评估的重要性。

研究设计与样本

  • STRIDE试验的事后分析,共纳入792例早期症状性外周动脉疾病合并2型糖尿病患者,其中女性195例(24.6%),男性597例(75.4%)。
  • 主要终点为第52周恒定负荷平板试验中最大步行距离(MWD)相对基线的比值。

主要发现

  • 女性与男性基线几何平均MWD分别为187.3米(变异系数0.6)和191.5米(变异系数0.6)。
  • 第52周MWD改善在兩性中一致倾向于司美格鲁肽治疗(交互作用P值=0.65)。
  • 第57周MWD改善趋势在两性中一致倾向于司美格鲁肽治疗(交互作用P值=0.53)。
  • 第52周无痛步行距离改善在两性中一致倾向于司美格鲁肽(交互作用P值=0.80)。
  • 司美格鲁肽在外周动脉疾病特异性生活质量(Vascular Quality of Life Questionnaire-6)方面的改善在两性中与总体试验结果一致。

临床怎么用

  • 对于外周动脉疾病合并2型糖尿病的患者,司美格鲁肽1.0 mg可作为改善功能结局的选择,且疗效不受性别影响。
  • 临床中应关注女性外周动脉疾病患者与男性的基线特征差异,如合并症和抗血小板治疗使用情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peripheral artery disease (PAD) is prevalent in women and men with type 2 diabetes (T2D). Sex-based differences exist in its epidemiology, clinical presentation, functional impact, outcomes, and potentially in responses to treatments. Recently, semaglutide 1.0 mg has been shown to improve functional outcomes and health-related quality of life in individuals with early symptomatic PAD and T2D in the STRIDE trial. OBJECTIVES: The objective of this study was to describe baseline characteristics, functional status, and therapeutic efficacy of once-weekly semaglutide 1.0 mg between females and males with PAD and T2D as a post hoc analysis from the STRIDE trial. METHODS: The primary endpoint in STRIDE was the ratio to baseline in maximum walking distance (MWD) at week 52 on a constant load treadmill. Confirmatory secondary endpoints included change in MWD at week 57, change in pain-free walking distance at week 52, and change in PAD-specific Vascular Quality of Life Questionnaire-6 total score from baseline to week 52. Herein, we report the outcomes analyzed by sex. RESULTS: Of 792 participants, 195 (24.6%) were female and 597 (75.4%) were male. Females were younger, had lower rates of smoking, lower prevalence of concomitant coronary artery disease and heart failure, and less frequent use of antiplatelet therapies compared with males. Geometric mean MWD at baseline was 187.3 m (coefficient of variation: 0.6) and 191.5 m (coefficient of variation: 0.6) in females and males, respectively. At week 52, there was a consistent improvement in MWD across sexes, which favored semaglutide treatment (P-interaction value = 0.65). At week 57, there was a consistent trend for improved MWD that favored semaglutide treatment for both females and males (P interaction = 0.53). Improvement in pain-free walking distance was consistent across sexes at week 52 in favor of semaglutide (P interaction = 0.80). Likewise, PAD-specific quality of life (assessed using Vascular Quality of Life Questionnaire-6) improvements with semaglutide in both sexes were consistent with the overall trial. CONCLUSIONS: In this post hoc analysis from STRIDE, semaglutide 1.0 mg exhibited consistent improvements in functional outcomes in people with early symptomatic PAD and T2D regardless of sex. Females with PAD demonstrated differences in baseline demographics and treatment patterns compared with males, highlighting the importance of sex-specific evaluation in PAD trials.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Verma S, Catarig AM, Houlind K, et al. Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial. J Am Coll Cardiol. 2025. PMID: 40892617. doi:10.1016/j.jacc.2025.08.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。